Rett syndrome is a neurodevelopmental disorder that primarily affects girls, most of whom have mutations in the transcription regulatory gene MECP2. However, mutations in MECP2 also have been ...

Results Of the 50 women with classic Rett syndrome, 94% had epilepsy (26% drug-resistant), 20% showed extrapyramidal signs, 40% sleep problems and 36% behavioural disorders. Eighty-six % patients ...

Trofinetide is intended to treat Rett syndrome, a neurodevelopmental disorder. Credit: SewCreamStudio/Shutterstock. Acadia Pharmaceuticals has submitted a marketing ...

variable-age onset idiopathic generalized epilepsy syndrome (MONDO:0800487) Rett syndrome, MECP2-related, crab-eating macaque (MONDO:1012890) XY sex reversal, SRY-related, horse (MONDO:1012653) ...

Neuren Pharmaceuticals has announced it has received its share of the net proceeds from the sale of the Rare Pediatric ...

Neuren’s partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment of Rett syndrome Compumedics achieves a record $32.8m in sales orders in H1 ...

More news: Neuren Pharmaceuticals was the worst performing ASX 200 company in early trading after its US partner Acadia Pharmaceuticals applied for approval to market its Rett syndrome treatment, ...

(Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome ...